- Home
- IMTX vs ORKA Comparison
IMTX vs ORKA Comparison
Compare IMTX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- ORKA
- Stock Information
- Founded
- IMTX N/A
- ORKA 2004
- Country
- IMTX Germany
- ORKA United States
- Employees
- IMTX N/A
- ORKA N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IMTX Health Care
- ORKA Health Care
- Exchange
- IMTX Nasdaq
- ORKA Nasdaq
- Market Cap
- IMTX 1.1B
- ORKA 1.2B
- IPO Year
- IMTX N/A
- ORKA N/A
- Fundamental
- Price
- IMTX $10.25
- ORKA $27.20
- Analyst Decision
- IMTX Strong Buy
- ORKA Strong Buy
- Analyst Count
- IMTX 4
- ORKA 9
- Target Price
- IMTX $13.67
- ORKA $45.22
- AVG Volume (30 Days)
- IMTX 654.5K
- ORKA 388.3K
- Earning Date
- IMTX 11-14-2025
- ORKA 11-12-2025
- Dividend Yield
- IMTX N/A
- ORKA N/A
- EPS Growth
- IMTX N/A
- ORKA N/A
- EPS
- IMTX N/A
- ORKA N/A
- Revenue
- IMTX $152,823,253.00
- ORKA N/A
- Revenue This Year
- IMTX N/A
- ORKA N/A
- Revenue Next Year
- IMTX $13.52
- ORKA N/A
- P/E Ratio
- IMTX N/A
- ORKA N/A
- Revenue Growth
- IMTX 83.61
- ORKA N/A
- 52 Week Low
- IMTX $3.30
- ORKA $5.49
- 52 Week High
- IMTX $11.25
- ORKA $29.98
- Technical
- Relative Strength Index (RSI)
- IMTX 56.67
- ORKA 56.20
- Support Level
- IMTX $8.92
- ORKA $25.57
- Resistance Level
- IMTX $10.86
- ORKA $29.98
- Average True Range (ATR)
- IMTX 0.63
- ORKA 2.19
- MACD
- IMTX -0.05
- ORKA -0.43
- Stochastic Oscillator
- IMTX 71.66
- ORKA 36.81
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.